Korysso Therapeutics

Korysso Therapeutics is a biotechnology company focused on the discovery and development of novel therapies for neurodegenerative diseases characterized by protein misfolding. Founded by world-renowned researchers Dr. Virginia Lee and Dr. John Trojanowski from the University of Pennsylvania, the company leverages deep expertise in the pathology of tau and alpha-synuclein. Its primary research programs involve the development of high-affinity monoclonal antibodies designed to target and neutralize toxic protein aggregates in conditions such as Alzheimer's and Parkinson's disease. In 2020, Korysso Therapeutics was acquired by Bristol Myers Squibb to bolster its neuroscience pipeline and advance next-generation treatments for neurodegeneration.